# Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors

> **NCT00003109** · PHASE1 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** raltitrexed

## Key facts

- **NCT ID:** NCT00003109
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-12
- **Primary completion:** 2000-10
- **Final completion:** 2001-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2013-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003109, "Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00003109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*